Commit Biologics Company Profile, Contacts & Intelligence

Commit Biologics Overview

Commit Biologics (Commit) is a pioneer in activating the complement system to kill specific target cells, with applications in cancers and autoimmune diseases. Spun out of Aarhus University, and building on more than three decades of research, Commit’s Bispecific Complement Engaging (BiCE™) platform can supercharge a conventional monoclonal antibody to activate the complement system more effectively. This is achieved by combining single domain antibodies that engage C1q, the starting point for the complement activation cascade, with an antibody that binds to a cellular target. The modular approach of the BiCE™ technology can be used to develop therapeutics across multiple tumor-associated antigens and immune cell targets. Complement is a largely untapped aspect of the body’s natural immune system that leverages both the direct cytolytic activity of complement along with its ability to bridge recruitment and activation of both innate and adaptive immune cells – a new approach to killing cells which can be used in combination or on a standalone basis. Commit is backed by major investors including Bioqube Ventures and Novo Holdings, as well as initial funding from the Bio Innovation Institute from Denmark.

Headquarters

Dk

Website

commitbio.com

Industry

Biotechnology

Founded

2021

Stock Symbol

LISTI

Commit Biologics Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

Commit Biologics People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to Commit Biologics

Explore companies in related markets and compare their industry and employee estimates.